Our proprietary topical liposomal JD-004 cream, lotion, and powder are being developed to help promote rapid wound healing while delivering analgesic activity at the same time. Combined with our IV as well as oral liposomal JD-004 formulations, the burn patient will receive optimal salicylate therapy and potentially have a decreased need for opioids.
As per the Congressionally Directed Medical Research Programs (CDMRPP), “According to the American Burn Association, nearly 500,000 patients in the United States require treatment for burn injuries annually with 40,000 of those patients requiring acute inpatient care; an average of 3000 patients die annually from burn injuries. Military burns are often devastating and more severe than burns obtained in the civilian setting. The majority of combat burns result from explosive device detonation, leading to a greater Injury Severity Score, an increase in inhalation injuries, and a larger, full-thickness burn size. Burns have comprised some 5-20% of the casualties sustained in post-World War II conflicts. From 2006-2018, the Defense Medical Epidemiology Database reports nearly 130,000 ambulatory visits with a primary burn injury diagnosis code among active component Service members. The mean total healthcare cost per burn patient in high income countries has been estimated at $88,218 (range $704-$717,306).“